Prilenia and Ferrer are enrolling the primary participant within the PREVAiLS Section III examine
Prilenia Therapeutics and Ferrer have enrolled the primary participant within the pivotal Section III PREVAiLS medical trial, evaluating pridopidine in people with quickly progressive amyotrophic lateral sclerosis (ALS) early in illness development.
Enrollment occurred at Mass Common Brigham, underneath the supervision of co-director of the MGH Neurological Scientific Analysis Institute and PREVAiLS principal investigator Sabrina Paganoni.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
The examine is predicated on information from a subgroup evaluation of individuals with quickly progressive ALS early of their illness course noticed within the Section II HEALEY ALS platform trial.
Though the HEALEY examine total didn’t meet its major or secondary endpoints, analyzes confirmed results in individuals with fast development, which PREVAiLS goals to substantiate.
The PREVAiLS examine shall be performed in as much as 60 ALS facilities in 13 nations.
This trial has already began or will quickly begin at 11 websites, with additional recruitment anticipated at further websites within the European Union, Canada, Nice Britain, Israel and the US within the coming months.
It’s structured as a 48-week, randomized (three to 2 occasions pridopidine to placebo), placebo-controlled examine with a subsequent open-label extension of 48 weeks.
Contributors will need to have particular or possible ALS in accordance with the El Escorial Standards and inside 18 months of symptom onset.
The first endpoint is change from baseline within the Amyotrophic Lateral Sclerosis Useful Ranking Scale – Revised (ALSFRS-R), adjusted for mortality at 48 weeks.
Secondary and exploratory outcomes included survival, speech and respiratory perform, bulbar measures, high quality of life and biomarkers.
The remedy has demonstrated a positive security profile in additional than 1,600 individuals, a few of whom have been handled for as much as seven years.
Paganoni mentioned: “Pridopidine is a sigma-1 receptor (S1R) agonist. The S1R has been proven to play a task in stimulating a number of neuroprotective pathways which can be disrupted in neurodegenerative ailments corresponding to ALS and Huntington’s illness.
“Enrolling the primary participant on this confirmatory examine is a milestone in our seek for potential new therapeutic choices that will assist gradual illness development, protect perform, protect speech and lengthen survival – key targets of early ALS remedy.”
In December 2025, the U.S. Meals and Drug Administration granted permission to Prilenia Therapeutics and Ferrer to provoke a Section III trial of pridopidine in people with quickly progressive ALS within the early levels of the illness.
